Rocket Pharmaceuticals received $35 million and may request more through a loan facility, adding cash for its work. Interest, repayment duties, and a claim on nearly all its assets leave its outlook balanced.
The cash gives Rocket more room to fund its work, and $35 million has already arrived. But the loan carries interest, requires repayment, and is backed by nearly all company assets, including intellectual property. Later borrowing depends on milestones or lender approval, so the full amount is not guaranteed. These competing terms leave the outlook balanced.
Hercules Capital is named as agent for the lenders in Rocket's loan, but the filing gives no amount attributable to Hercules. It does not show a clear change to Hercules Capital's outlook.
Follow Rocket Pharmaceuticals, Inc. (RCKT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for RCKT